Back to Defining Moments
Inspirational people, scientific discoveries, and transformative partnerships that have shaped who we are.
In 2005, the results of the Phase III MARINA study were presented at the American Society of Retina Specialists Annual Meeting, paving the way for a new way to treat wet age-related macular degeneration (wAMD), a leading cause of blindness.
Genentech’s scientists faced a number of challenges on the road to their first FDA approval.
With the FDA approval of its very first medicine, Genentech makes a long-term commitment to patient access.
Tell us what you think about our company, products, or website.
The way to do research is to attack the facts at the point of greatest astonishment.